Anti-Arrhythmia Agents

• 

  Subject Areas on Research

  • 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. 
  • A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. 
  • A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. 
  • Action potential and QT prolongation not sufficient to cause Torsade de Pointes: role of action potential triangulation. 
  • Activating PKC-β1 at the blood-brain barrier reverses induction of P-glycoprotein activity by dioxin and restores drug delivery to the CNS. 
  • Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. 
  • After myocardial infarction. How to determine future risk and what to do then. 
  • All that glitters is not gold. 
  • Amiodarone and reperfusion ventricular fibrillation. 
  • Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. 
  • Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 
  • Amiodarone versus implantable cardioverter defibrillator for asymptomatic nonsustained ventricular tachycardia in nonischemic dilated cardiomyopathy. 
  • Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • An adverse reaction to a medication given to treat an adverse reaction: a teachable moment. 
  • Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. 
  • Anesthetic induction with fentanyl and intravenous lidocaine for coronary artery surgery. 
  • Anesthetic management of an AAI pacemaker patient with paroxysmal atrial fibrillation during colorectal surgery. 
  • Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction. 
  • Antiarrhythmic agents in older patients. Current state of knowledge. 
  • Antiarrhythmic drug action. Blockade of the inward sodium current. 
  • Antiarrhythmic drug action: selective depression of hypoxic cardiac cells. 
  • Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. 
  • Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. 
  • Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). 
  • Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. 
  • Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. 
  • Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada. 
  • Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug? 
  • Atrial fibrillation ablation in practice: assessing CABANA generalizability. 
  • Atrial fibrillation in heart failure: what should we do? 
  • Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. 
  • Atrial fibrillation: conventional wisdom reappraised. 
  • Atrial fibrillation: rate control versus maintenance of sinus rhythm. 
  • Atrial flutter, atrial fibrillation, and other primary atrial tachycardias. 
  • Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. 
  • Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. 
  • Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. 
  • Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. 
  • Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics. 
  • Block and modulation of cardiac Na+ channels by antiarrhythmic drugs, neurotransmitters and hormones. 
  • Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells. 
  • CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift? 
  • CASE 6--2012: suspected amiodarone hepatotoxicity after cardiac surgery. 
  • CE coupling with end-column electrochemiluminescence detection for chiral separation of disopyramide. 
  • Can polymorphisms predict response to antiarrhythmic drugs in atrial fibrillation? 
  • Cardiac arrest in young, ostensibly healthy patients: clinical, hemodynamic, and electrophysiologic findings. 
  • Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. 
  • Cardiac responses to the intrapericardial delivery of metoprolol: targeted delivery compared to intravenous administration. 
  • Cardioversion and subsequent quality of life and natural history of atrial fibrillation. 
  • Cases from the Osler Medical Service at Johns Hopkins University. Digitalis toxicity with bidirectional ventricular tachycardia. 
  • Catheter Ablation Compared With Drug Therapy for Atrial Fibrillation-Reply. 
  • Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 
  • Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. 
  • Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. 
  • Cellular electrophysiology of clofilium, a new antifibrillatory agent, in normal and ischemic canine Purkinje fibers. 
  • Changes in atrioventricular conduction properties with refractory-period modulation. 
  • Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. 
  • Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Cohort profile: patient characteristics and quality-of-life measurements for newly-referred patients with atrial fibrillation-Keio interhospital Cardiovascular Studies-atrial fibrillation (KiCS-AF). 
  • Combination ethacizin and ethmozin treatment of resistant ventricular ectopy: theoretical, experimental, and clinical study. 
  • Comparative effectiveness of digoxin and propranolol for supraventricular tachycardia in infants. 
  • Comparative effectiveness of pharmacotherapies for prevention of atrial fibrillation following coronary artery bypass surgery. 
  • Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. 
  • Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry. 
  • Comparison of mortality in patients treated with propafenone to those treated with a variety of antiarrhythmic drugs for supraventricular arrhythmias. 
  • Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. 
  • Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs. 
  • Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? 
  • Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series. 
  • Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias. 
  • Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. 
  • Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. 
  • Cryoablation for atrial fibrillation and antiarrhythmic drug pretreatment: a single referral center experience. 
  • Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator. 
  • Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Designing clinical trials for paroxysmal atrial tachycardia and other paroxysmal arrhythmias. 
  • Dexmedetomidine: therapeutic use for the termination of reentrant supraventricular tachycardia. 
  • Differences in inducibility and prognosis of in-hospital versus out-of-hospital identified nonsustained ventricular tachycardia in patients with coronary artery disease: clinical and trial design implications. 
  • Digoxin and Mortality in Patients With Atrial Fibrillation. 
  • Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Distributed decision support using a web-based interface: prevention of sudden cardiac death. 
  • Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials. 
  • Dofetilide dose reductions and discontinuations in women compared with men. 
  • Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. 
  • Double-blind randomized comparison of intravenous tocainide versus lidocaine in the treatment of chronic ventricular arrhythmias. 
  • Dronedarone in high-risk permanent atrial fibrillation. 
  • Drug Provocation Testing in Brugada Syndrome: A Test of Uncertain Significance. 
  • Drug-drug interactions in older adults: which ones matter? 
  • Early experience with intravenous sotalol in children with and without congenital heart disease. 
  • Early management of atrial fibrillation to prevent cardiovascular complications. 
  • Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction. 
  • Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. 
  • Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. 
  • Effect of amiodarone-induced hyperthyroidism on left ventricular outflow obstruction after septal myectomy for hypertrophic cardiomyopathy. 
  • Effect of dofetilide on survival in patients with supraventricular arrhythmias. 
  • Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. 
  • Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. 
  • Effects of ZD6169, a K ATP channel opener, on neurally-mediated plasma extravasation in the rat urinary bladder induced by chemical or electrical stimulation of nerves. 
  • Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation. 
  • Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. 
  • Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. 
  • Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. 
  • Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. 
  • Electrophysiological mechanisms of the anti-arrhythmic effects of omega-3 fatty acids. 
  • Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential. 
  • Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. 
  • Ethacizin blockade of calcium channels: a test of the guarded receptor hypothesis. 
  • European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). 
  • Experience with moricizine HCl in children with supraventricular tachycardia. 
  • Exploring the role of pH in modulating the effects of lidocaine in virtual ischemic tissue. 
  • Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AF. 
  • Frequency of high-risk use of QT-prolonging medications. 
  • Functional status, heart rate, and rhythm abnormalities in 521 Fontan patients 6 to 18 years of age. 
  • Get With The Guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. 
  • Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines-Atrial Fibrillation Registry. 
  • Heart Failure and Atrial Fibrillation, Like Fire and Fury. 
  • Hemodynamic effects of the antiarrhythmic drug pirmenol. 
  • Highlights of Heart Rhythm 2005, the Annual Scientific Sessions of the Heart Rhythm Society, May 4-7, 2005, New Orleans, Louisiana. 
  • Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. 
  • Implications of the LEGACY trial on US Atrial Fibrillation Patients: An NCDR Research to Practice (R2P) Project. 
  • Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. 
  • In-hospital management of patients with atrial flutter. 
  • Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry. 
  • Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). 
  • Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial. 
  • Insights into the contemporary epidemiology and outpatient management of congestive heart failure. 
  • Intentional and unintentional medication non-adherence in African Americans: Insights from the Jackson Heart Study. 
  • Interpreting the Results of Intention-to-Treat, Per-Protocol, and As-Treated Analyses of Clinical Trials. 
  • Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes? 
  • Is newer better? Propafenone versus quinidine for conversion of atrial fibrillation. 
  • Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? 
  • Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? 
  • Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study. 
  • Left atrial tachycardia originating from the mitral annulus-aorta junction. 
  • Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. 
  • Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. 
  • Long-term oral anticoagulant after catheter ablation for atrial fibrillation. 
  • Loss of efficacy during long-term cifenline therapy: development of antiarrhythmic resistance? 
  • MADIT-II: clinical implications. 
  • Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: a randomized controlled study. 
  • Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. 
  • Management of pediatric tachyarrhythmias on mechanical support. 
  • Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. 
  • Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. 
  • Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination. 
  • Mechanisms of apparent affinity variation of guarded receptors. 
  • Mechanisms of atrial fibrillation and action of drugs used in its management. 
  • Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. 
  • Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. 
  • Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement? 
  • Models of drug interaction with the sodium channel. 
  • Modulating intraventricular conduction through competition of two class 1 antiarrhythmic agents: experience with ethacizin and lidocaine in canine heart. 
  • Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. 
  • Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. 
  • Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. 
  • New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance. 
  • New drug application strategies for supraventricular arrhythmias. 
  • No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Obstructive sleep apnea is associated with increased rotor burden in patients undergoing focal impulse and rotor modification guided atrial fibrillation ablation. 
  • On the mechanism of action of antiarrhythmic agents. 
  • Ongoing Management of Patients With Supraventricular Tachycardia. 
  • Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. 
  • Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. 
  • Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation. 
  • Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. 
  • Pediatric electrophysiology. 
  • Perioperative Management of Flecainide: A Problem-Based Learning Discussion. 
  • Perioperative cardiac arrhythmias. 
  • Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers. 
  • Pharmacokinetic studies: their role in determining therapeutic efficacy of agents designed to prevent sudden death. 
  • Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. 
  • Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. 
  • Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. 
  • Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. 
  • Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. 
  • Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. 
  • Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. 
  • Prevention of recurrent sudden cardiac arrest: role of provocative electropharmacologic testing. 
  • Prevention of sudden death in patients with coronary artery disease. 
  • Previously unreported adverse reaction to encainide. 
  • Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. 
  • Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. 
  • Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments. 
  • Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. 
  • Propafenone-induced acute generalized exanthematous pustulosis. 
  • Propafenone: an effective agent for the management of supraventricular arrhythmias. 
  • Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. 
  • Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. 
  • Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. 
  • Publishing web-based guidelines using interactive decision models. 
  • Pulmonary edema post-cardioversion: a potential calcium signalling problem. 
  • Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. 
  • Quality of life in patients with implantable cardioverter-defibrillator: systematic review of randomized controlled trials. 
  • Quality of life with defibrillator therapy or amiodarone in heart failure. 
  • Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. 
  • Ranolazine reduces atrial fibrillatory wave frequency. 
  • Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. 
  • Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. 
  • Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. 
  • Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. 
  • Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. 
  • Regional anesthesia for thyroidectomy in two patients with amiodarone-induced hyperthyroidism. 
  • Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial. 
  • Reply: Digoxin Use in Atrial Fibrillation: Minimizing and Refining its Use When Still Needed. 
  • Rethinking papillary muscle resection for refractory ventricular tachycardia in the LVAD era. A case report. 
  • Review: In noncardiac surgery, amiodarone, β-blocker, or statin prophylaxis reduces postoperative AF. 
  • Rhythm control in atrial fibrillation. 
  • Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. 
  • Rhythm control versus rate control for atrial fibrillation and heart failure. 
  • Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. 
  • Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. 
  • SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. 
  • Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. 
  • Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998. 
  • Several new considerations in mitral valve repair. 
  • Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. 
  • Sinus node dysfunction. 
  • Slow sodium channel inactivation and use-dependent block modulated by the same domain IV S6 residue. 
  • State dependence of ethacizin and ethmozin block of sodium current in voltage clamped and internally perfused cardiac Purkinje cells. 
  • Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines - Heart Failure Program). 
  • Supraventricular tachycardia in four young dogs. 
  • Surgical Maze procedure as a treatment for atrial fibrillation: a meta-analysis of randomized controlled trials. 
  • Surrogate end points in heart failure trials. 
  • Sympathectomy for Stabilization of Heart Failure Due to Drug-Refractory Ventricular Tachycardia. 
  • Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. 
  • The cardiac sodium channel: a target for antiarrhythmic drug action. 
  • The effect of bretylium tosylate on ventricular function. 
  • The effect of quinidine, propranolol and their combination on experimental atrial and ventricular arrhythmias. 
  • The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. 
  • The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. 
  • The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. 
  • Thyroid function in heart failure and impact on mortality. 
  • To be or not to be in normal sinus rhythm: what do we really know? 
  • Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database. 
  • Trends Over Time in Drug Administration During Adult In-Hospital Cardiac Arrest. 
  • Update on sick sinus syndrome, a cardiac disorder of aging. 
  • Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. 
  • Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. 
  • Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. 
  • Use of implantable cardioverter defibrillator and anti-arrhythmic agents in a parturient. 
  • Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Verapamil prolongs atrial fibrillation by evoking an intense sympathetic neurohumoral effect. 
  • Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. 
  • Wavelet formation in excitable cardiac tissue: the role of wavefront-obstacle interactions in initiating high-frequency fibrillatory-like arrhythmias. 
  • What happens when cardiac Na channel function is compromised? 2. Numerical studies of the vulnerable period in tissue altered by drugs. 
  • What to do with acute atrial fibrillation? 
  • When the body and appendage of the left atrium disagree: "Focal" atrial fibrillation-implications for atrial thrombus formation and risk of thromboembolism. 
  • Who are the MADIT patients? Multicenter Automatic Defibrillator Implantation Trial. 
  • [The combined effect of 2 first-line anti-arrhythmia drugs on the conduction velocity of myocardial stimulation]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Starmer, Charles Franklin, Professor Emeritus of Computer Science, Computer Science
  • Warner, David Samuel, Distinguished Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology